Page 48 - textbook5chapters
P. 48

1300 Technique of Intraperitoneal Chemotherapy: Normothermic and Hyperthermic

Table 5. Chemotherapy Agents With Activity                       prefer taxanes (paclitaxel/docetaxel) (36). The proposed
Enhanced by Hyperthermia That Can Be Given IP                    consensus of the ASPSM was for an inflow temperature of
                                                                 42°C with a volume of 3 liters for 90 minutes. It is clear that
cisplatin     irinotecan                                         the HIPEC field is open for much more research and, as
                                                                 with normothermic IP chemotherapy, it would be ideal if
carboplatin   melphalan                                          patients with EOC should receive this treatment modality
                                                                 as participants in research protocols. Table 6 summarizes
oxaliplatin   docetaxel                                          the recently concluded, ongoing and new clinical trials
                                                                 registered with clinicaltrials.gov. (40). It also reflects the
doxorubicin   mitomycin                                          heterogeneity of study designs, chemotherapy regimen
                                                                 and dosage and endpoints. Of interest, a few studies
mitoxantrone  vinorelbine                                        have focused on translational endpoints (NCT02073500,
                                                                 NCT02199171 and NCT02567253) as recent reports
Hyperthermic Intraperitoneal                                     would indicate that HIPEC may have a beneficial role in
Chemotherapy                                                     platinum resistant disease too (26, 30-32). A systematic
                                                                 review and meta-analysis showed a significantly better
The addition of moderate hyperthermia (39-44°C) has              overall survival (OS) benefit of HIPEC when added to
been proposed as a means of enhancing the effects of IP          CRS+ chemotherapy for both frontline and recurrent
chemotherapy in a technique called HIPEC (21). While             epithelial ovarian cancers at 1 year (OR 3.76, 95% CI
cancer cells are susceptible to heat alone, hyperthermia         1.81-7.82) and continued through 5 year (OR 3.46,
also enhances the activity of many chemotherapy agents           CI 2.19-5.48) and 8 years (OR 2.42, 95% CI 1.38-4.24)
in part by increasing cell uptake (Table 5) (22, 23).            respectively. For overall disease free survival, carboplatin
                                                                 was associated with an improved OS as compared to
    Following the initial report of HIPEC for                    mitomycin or cisplatin (29).
pseudomyxoma peritonei in 1979 by Dr John Spratt, (24)
the first woman with EOC appears to have been treated            Technique of HIPEC
in 1994 (25). Now more than 1500 cases of HIPEC in
ovarian cancers have been reported and subjected to              Whatever the technique or timing of HIPEC it is essential
meta-analysis, with a single completed randomized trial          to have a heat-exchange pump system that will heat the
(26) and many ongoing randomized controlled trials               perfusate and circulate it throughout the PC.
(27-39).
                                                                     A protocol should be in place for the handling of
    There are theoretical reasons why HIPEC could                chemotherapy agents in the operating room and recovery
reasonably be given at the time of surgery at several of         areas and for management of toxic waste. A dedicated
the natural history time-points of EOC including at the          team in the operating room is essential, including
time of front-line CRS, at CRS following neoadjuvant             anesthesiologist, surgeon, pump technician and nursing
chemotherapy, for consolidation and at CRS for recurrent         staff that will ensure efficient delivery with maximum
disease. HIPEC is generally given as a single treatment at       safety for the patient and operating team (41, 42).
the time of surgery with the intent of treating microscopic
cancer cells disturbed by the surgery, so-called ‘floaters’, or      HIPEC is performed under general anesthesia. The
microscopic or small volume macroscopic involvement              patient is placed supine or in Allen stirrups according
of peritoneal surfaces. HIPEC may be repeated at the             to procedure and surgeon preference. To monitor
time of second look surgery for consolidation and at the         core body temperature a heat sensor is placed in the
time of surgery for recurrent disease. It would not usually      esophagus and a urethral catheter with heat sensor probe
be considered as an isolated treatment but should always         is placed in the bladder. The skin is prepared widely. A
be given in association with subsequent intravenous              large sterile Ioban™-2 adhesive drape (3M Corp, St Paul,
chemotherapy.                                                    MN, USA) may be placed over the entire operative area
                                                                 prior to draping to reduce the chance of chemotherapy
    At the present time there are no proven ‘best’ drugs         contamination. The CRS is then performed as necessary
or treatment modalities (temperature and duration                to reduce peritoneal tumor volume to either no visible
of perfusion) for HIPEC. The American Society for                disease or less than 5mm (29). Although the vaginal
Peritoneal Surface Malignancy (ASPSM) conducted                  vault must be closed prior to HIPEC many surgeons will
a survey of its members and others using HIPEC for               leave reconstruction of bowel anastomoses until after.
EOC in an attempt to define current practice (Personal           Approximately one hour before HIPEC will be given
Communication: Jesus Esquivel, MD). No formal                    the anesthiologist takes steps to lower the patient’s core
consensus has been reached but a proposed consensus              temperature to 34-35°C, principally by lowering the air
included the use of carboplatin 800mg/m2 or cisplatin            temperature in the room and switching off the warming
75mg/m2 for platinum sensitive disease and mitomycin             blanket. The pump technician also starts to prepare the
40mg total dose (30mg initially and then 10mg at 45
minutes) for platinum resistant disease. Some groups
   43   44   45   46   47   48   49   50   51   52   53